Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide (‘laughing gas’)-induced anomalous states
Giulia Piazza, Georges Iskandar, Vanessa Hennessy, Hannah Zhao, K. Walsh, J. Mcdonnell, Devin B. Terhune, R. Das, Sunjeev K. Kamboj
Psychopharmacology March 26, 2022 DOI: 10.1007/s00213-022-06121-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Secondary analysis of pooled data from three previous studies Peer reviewed |
|---|---|
| Population | Healthy volunteers |
| Citations | 14 |
| Key points | Nitrous oxide produces dissociative states psychometrically similar to ketamine, and the CADSS and PSI tap largely non-overlapping experiences, supporting their combined use. |
Abstract
A significant obstacle to an improved understanding of pathological dissociative and psychosis-like states is the lack of readily implemented pharmacological models of these experiences. Ketamine has dissociative and psychotomimetic effects but can be difficult to use outside of medical and clinical-research facilities. Alternatively, nitrous oxide (N2O) — like ketamine, a dissociative anaesthetic and NMDAR antagonist — has numerous properties that make it an attractive alternative for modelling dissociation and psychosis. However, development and testing of such pharmacological models relies on well-characterized measurement instruments. To examine the factor structures of the Clinician Administered Dissociative States Scale (CADSS) and Psychotomimetic States Inventory (PSI) administered during N2O inhalation in healthy volunteers. Secondary analyses of data pooled from three previous N2O studies with healthy volunteers. Effect sizes for N2O-induced dissociation and psychotomimesis were comparable to effects reported in experimental studies with sub-anaesthetic ketamine in healthy volunteers. Although, like ketamine, a three-factor representation of N2O-induced dissociation was confirmed, and a more parsimonious two-factor model might be more appropriate. Bayesian exploratory factor analysis suggested that N2O-induced psychosis-like symptoms were adequately represented by two negative and two positive symptom factors. Hierarchical cluster analysis indicated minimal item overlap between the CADSS and PSI. N2O and ketamine produce psychometrically similar dissociative states, although parallels in their psychosis-like effects remain to be determined. The CADSS and PSI tap largely non-overlapping experiences under N2O and we propose the use of both measures (or similar instruments) to comprehensively assess anomalous subjective states produced by dissociative NMDAR antagonists.
Citations in the library
Cited by 10
- Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD The International Journal of Neuropsychopharmacology December 14, 2022
- Effects of a dissociative drug on fronto-limbic resting-state functional connectivity in individuals with posttraumatic stress disorder: a randomized controlled pilot study. Psychopharmacology October 23, 2023
- The Induction of Dissociative States: A Meta-Analysis. Biological Psychiatry Global Open Science July 1, 2025
- How-To Study Dissociative Symptoms in a Broad Range of Mental Disorders: A Methodological Primer Journal of Trauma & Dissociation April 7, 2025
- Acute Psychosis and Dissociative Syndrome Following Binge Recreational Nitrous Oxide Use: A Case Report Cureus September 17, 2026
and 5 more in the library
Cites 26
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS) Journal of Traumatic Stress 1998
- Ketamine use: a review Addiction July 21, 2011
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression American Journal of Psychiatry April 8, 2016
and 21 more in the library